Navigation Links
Enbrel® (etanercept) Significantly Improved Scalp Involvement in Patients with Moderate to Severe Plaque Psoriasis
Date:2/4/2011

THOUSAND OAKS, Calif. and COLLEGEVILLE, Pa., Feb. 4, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) and Pfizer Inc. (NYSE: PFE) today announced results from a new trial that demonstrated Enbrel® (etanercept) significantly improved scalp involvement in adult patients with moderate to severe plaque psoriasis, compared with placebo. The data will be presented today at the 69th Annual American Academy of Dermatology (AAD) meeting in New Orleans, La.  

"At least half of people with plaque psoriasis have involvement on their scalp, which may contribute to feelings of embarrassment associated with this condition," said lead author Jerry Bagel, M.D., medical director, Psoriasis Treatment Center of Central New Jersey. "These data reinforce the efficacy and safety profile of ENBREL for adult patients with moderate to severe plaque psoriasis with scalp involvement."

In this trial, patients were randomized to either 12 weeks of ENBREL 50 mg twice weekly followed by 12 weeks of ENBREL 50 mg once weekly (Group A), or 12 weeks of placebo twice weekly followed by 12 weeks of ENBREL 50 mg twice weekly (Group B). This trial met its primary endpoint of mean percent improvement from baseline in Psoriasis Scalp Severity Index (PSSI) with 87 percent PSSI improvement in Group A compared with 20 percent in Group B at week 12 (P<0.0001). The PSSI response to ENBREL for patients in Group A was maintained through 24 weeks despite patients switching to a lower dose (91 percent). Patients in Group B saw a mean percent improvement in their PSSI score of 79 percent at week 24, similar to that achieved by the Group A patients at week 12.

In addition to the improvement in scalp involvement, in an exploratory analysis, the mean percent improvement from baseline in Psoriasis Area Severity Index (PASI) was 74
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement
2. New Study Shows Tapentadol Extended Release (ER) May Significantly Reduce Average Pain Intensity for Diabetic Patients Suffering From Painful Peripheral Neuropathy
3. Newly Published Data Demonstrates Caldolor® Significantly Reduces Pain and Morphine Use in Post-Operative Patients
4. Correction: New Mexico Software Unveils Additional Software Significantly Expanding Availability of Its Telemedicine Services
5. New Mexico Software Unveils Additional Software Significantly Expanding Availability of Its Telemedicine Services
6. Study Shows BSGI/MBI Contributes Significantly to Patient Management with Its Ability to Detect Breast Cancer in Difficult to Diagnose Patients
7. XGEVA™ (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer
8. Adding INSPRA® (eplerenone) to Standard Therapy Significantly Reduces the Risk of CV Mortality and Morbidity in Patients With Chronic Heart Failure With Mild Symptoms, Study Shows
9. Study Published in New England Journal of Medicine Shows Nplate® Significantly Reduces Treatment Failure and Splenectomy Rate in Patients With Chronic ITP
10. CyberKnife® VSI™ System Expands Treatment Applications and Significantly Reduces Treatment Times
11. Abiraterone Acetate Significantly Improved Overall Survival for Patients with Metastatic Advanced Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... , June 29, 2015  Isis Pharmaceuticals, Inc. (NASDAQ: ... added to the Russell 1000 Index, effective June 26, ... the large-cap segment of the U.S. equity universe. It ... includes approximately 1000 of the largest securities based on ... membership. "We are pleased to be added ...
(Date:6/29/2015)... Axxess , an industry leader in ... vendor accredited by the American Nursing Credentialing Center – ... agencies select the right revenue cycle management (RCM) system ... business. Research by American Health Information Management ... a decrease in productivity of 54.4 - 69 percent ...
(Date:6/29/2015)... 29, 2015  Arbor Solution has added another ... high-powered, multi-functional M2150 offers two platforms: ... Core i5-4402E 1.6 GHz processor and i5-4422E ... and computing performance. Integrated Intel® HD Graphics 4600 ... suited for graphics-intense applications in operating rooms, clinical ...
Breaking Medicine Technology:ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 2ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 3Axxess Releases eGuide for Home Health Agencies, Revenue Cycle Management: What You Must Do Now - to Succeed! 2Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 2Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 3
... N.J., July 05, 2007 /PRNewswire/ -- Results ... open-label, Phase,3 study showed that 77 percent ... 600 mg tablets with,100 mg ritonavir (PREZISTA/r) ... of antiretroviral (ARV) agents, reached a,plasma viral ...
... 2007 - ZIOPHARM,Oncology, Inc. (NASDAQ: ZIOP) announces ... II trial of ZIO-201 (isophosphoramide mustard,- IPM) ... at the,European Society of Medical Oncology (ESMO) ... The abstract entitled, "Phase-I/II,Study of IPM (ZIO-201) ...
Cached Medicine Technology:New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 2New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 3New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 4New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 5New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 6New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 7New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 8Positive ZIO-201 Interim Phase II Sarcoma Data Presented at,European Society for Medical Oncology 2Positive ZIO-201 Interim Phase II Sarcoma Data Presented at,European Society for Medical Oncology 3
(Date:6/29/2015)... ... June 29, 2015 , ... Healthpointe, ... surgeon, Dr. John A. Mitamura, MD., PhD into their world-class multidisciplinary team of ... including Long Beach , Irwindale and La Tijera-Los Angeles. , Orthopedic ...
(Date:6/29/2015)... , ... June 29, 2015 , ... ... news that the European Medicines Agency (EMA) has granted accelerated approval of Bristol-Myers ... a global public health threat and the approval of nivolumab for patients with ...
(Date:6/29/2015)... ... June 29, 2015 , ... ... announces the Fresh Plus Diaper, a baby invention that makes parenthood less tiring ... projected to reach a market value of USD 52.2 billion in 2017," says ...
(Date:6/29/2015)... ... June 29, 2015 , ... Two ... against C.R. Bard, Inc. and Ethicon, Inc. continue to move forward in New ... Management Conference is to be convened on Thursday, July 23rd at 12:00 p.m. ...
(Date:6/29/2015)... MD (PRWEB) , ... June 29, 2015 , ... OR ... features a revitalized look and feel, as well as a redesigned logo and weekly ... used to, but is now more user-friendly and easier to navigate. , In ...
Breaking Medicine News(10 mins):Health News:Renowned Orthopedic and Spine Surgeon Joins Healthpointe in Long Beach 2Health News:Renowned Orthopedic and Spine Surgeon Joins Healthpointe in Long Beach 3Health News:Society for Immunotherapy of Cancer Reacts to EMA Approval of Nivolumab for Treatment of Metastatic Melanoma 2Health News:Society for Immunotherapy of Cancer Reacts to EMA Approval of Nivolumab for Treatment of Metastatic Melanoma 3Health News:Bringing Up Baby...Millenials Should Check World Patent Marketing's New Baby Invention 2Health News:Bringing Up Baby...Millenials Should Check World Patent Marketing's New Baby Invention 3Health News:Bringing Up Baby...Millenials Should Check World Patent Marketing's New Baby Invention 4Health News:Bringing Up Baby...Millenials Should Check World Patent Marketing's New Baby Invention 5Health News:Transvaginal Mesh Lawsuit News: New Jersey Court Overseeing Thousands of Ethicon, C.R. Bard Pelvic Mesh Claims Schedules July Conference 2Health News:Transvaginal Mesh Lawsuit News: New Jersey Court Overseeing Thousands of Ethicon, C.R. Bard Pelvic Mesh Claims Schedules July Conference 3Health News:Transvaginal Mesh Lawsuit News: New Jersey Court Overseeing Thousands of Ethicon, C.R. Bard Pelvic Mesh Claims Schedules July Conference 4Health News:OR Manager Launches New Website 2
... light, scientists from the National Institute of Standards and Technology ... they can detect molecules that may be markers for diseases ... yet to be tested in clinical trials, it may someday ... sampling their breath, according to the research team from JILA, ...
... in Baltimore ... market, ... announced that Medifast Franchise Systems has sold its,first franchise of Medifast Weight ... Control Centers in the Greater,Baltimore Metropolitan Area., The entire build-out process ...
... RELEASE , Fighting fat bloom can mean ... Agricultural and Food Chemistry , Chemists in England and ... boxes of Valentines Day chocolates, and other goodies, looking fresher ... films on the outside of chocolate, is scheduled for the ...
... Uninsured, those on Medicaid more likely to be diagnosed ... Feb. 18 (HealthDay News) -- People who either have ... likely to be diagnosed with advanced cancers than people ... Cancer Society report. , At a time when more ...
... - the ,Must Join, Social Networking Web Site ... Crystal Light beverage,brand has partnered with actress and musical ... Web site that will help women,harness the power of ... for one another -- to empower, inspire, challenge and,sustain ...
... Hospital,this week opens a new 16-bed inpatient behavioral health ... -- with an innovative way of caring for patients.,Psychiatrists ... continuity and a better experience for patients., The ... for,patients once they arrive in the emergency department throughout ...
Cached Medicine News:Health News:Scientists using laser light to detect potential diseases via breath samples, says new study 2Health News:Scientists using laser light to detect potential diseases via breath samples, says new study 3Health News:Medifast Franchise Systems Sells First Territory in Baltimore 2Health News:Medifast Franchise Systems Sells First Territory in Baltimore 3Health News:American Chemical Society's Weekly PressPac -- Feb. 13, 2008 2Health News:American Chemical Society's Weekly PressPac -- Feb. 13, 2008 3Health News:American Chemical Society's Weekly PressPac -- Feb. 13, 2008 4Health News:American Chemical Society's Weekly PressPac -- Feb. 13, 2008 5Health News:American Chemical Society's Weekly PressPac -- Feb. 13, 2008 6Health News:American Chemical Society's Weekly PressPac -- Feb. 13, 2008 7Health News:American Chemical Society's Weekly PressPac -- Feb. 13, 2008 8Health News:American Chemical Society's Weekly PressPac -- Feb. 13, 2008 9Health News:Timely Cancer Diagnosis Linked to Insurance Status 2Health News:Timely Cancer Diagnosis Linked to Insurance Status 3Health News:Crystal Light and Mandy Moore Launch Unique Online Wellness Community for Women 2Health News:Crystal Light and Mandy Moore Launch Unique Online Wellness Community for Women 3Health News:Regions Hospital to Open New Inpatient Behavioral Health Unit 2
Nordan tying forceps, straight, titanium, 6.5 mm tying platforms....
Harms-Tuebingen tying forceps, straight, 6 mm tying platforms....
Castroviejo straight tying forceps, straight shafts, 5 mm tying platforms, wide handle....
Shepard tying forceps, round curved platform 8 mm, 8.5 cm....
Medicine Products: